Skip to main content

Adjuvant Metastatic Urothelial Cancer CA244-0012 IZABRIGHT-Bladder01

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • Sacramento
  • Palo Alto
  • Santa Rosa

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment

Nitin Rohatgi
Nitin Rohatgi
Principal investigator
View Profile

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?